Location permission needed for a better experience.
How can we help you?
CV
MEMBERSHIPS
PUBLICATIONS
EDUCATION
  • 2000 Marmara Üniversitesi Tıp Fakültesi Hematoloji
  • 1994 Karadeniz Teknik Üniversitesi Tıp Fakültesi İç Hastalıkları
  • 1988 Ankara Üniversitesi Tıp Fakültesi
EXPERIENCE
  • 2019 Acıbadem Sağlık Grubu
  • 2016 - 2019 Koç Üniversitesi Tıp Fakültesi İç Hastalıkları Ana Bilim Dalı Başkanı
  • 2016 - 2019 Koç Üniversitesi Tıp Fakültesi İç Hast. Anabilim Dalı kurucusu ve Başkanı
  • 2013 - 2019 Koç Üniversitesi Tıp Fakültesi İç Hastalıkları Koordinatörü
  • 2008 - 2017 Amerikan Hastanesi Terapötik Aferez Sorumlu Hekimi
  • 2013 Koç Üniversitesi Tıp Fakültesi / Profesör
  • 2010 - 2013 Şişli Memorial Hastanesi Kemik İliği Nakli Ünitesi Direktörü
  • 2011 - 2012 Şişli Memorial Hastanesi Kemik İliği Nakli Ünitesi kurucusu ve Direktörü / Doçent
  • 2010 WHO (Dünya Sağlık Örgütü) ve UN (Birleşmiş Milletler) Hekimi
  • 2008 V.K.V. Amerikan Hastanesi Hematoloji Bölümü / Doçent
  • 2006 - 2008 Marmara Üniversitesi / İç Hastalıkları / Hematoloji / Doçent
  • 2001 - 2006 Marmara Üniversitesi / İç Hastalıkları / Hematoloji / Yardımcı Doç.
  • 2004 - 2005 Hematopetic Stem Cell Transplantation Program / Department of Medicine / Feinberg School of Medicine / Northwestern University / Misafir Öğretim Üyesi
  • 1998 - 2001 Marmara Üniversitesi / İç Hastalıkları / Hematoloji / Uzman Dr.
  • 1997 - 2000 Marmara Üniversitesi Tıp Fakültesi / İç Hastalıkları / Hematoloji / Dr.Ar.Gör.
  • 1994 - 1997 Milli Eğitim Bakanlığı Beşevler Sağlık Eğitim Merkezi / Uzman Dr.
  • 1989 - 1994 İç Hastalıkları Tıp Fakültesi Karadeniz Teknik Üniversitesi / Dr.Ar.Gör.
MEMBERSHIPS
  • Türk Tabipleri Birliği
  • Kanser Savaşçıları Derneği
  • European Hematology Association
  • American Society of Hematology
  • European Bone Marrow Transplantation Registry
  • Türk İç Hastalıkları Uzmanlık Derneği
  • Türk Hematoloji Derneği
  • MDS Foundation
  • Türk İmmünoloji Derneği
  • Üniversite Öğretim Üyeleri Derneği
  • Kök Hücre ve Rejeneratif Tıp Derneği
  • Türk Tromboz ve Hemostaz Derneği
PUBLICATIONS
  • A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia Turk J Haematol. 2019 Jul 22. doi: 10.4274/tjh.galenos.2019.2018.0307. Cekdemir D, Guvenc S, Ozdemirkiran F, Eser A, Toptas T, Ozkocaman V, Haydaroglu Sahin H, Ermis Turak E, Esen R, Comert M, Sadri S, Aslaner M,
  • The role of atopy in the pathogenesis of bleomycin pulmonary toxicity Respiratory Medicine. (2019) Ozyigit, L. P., Aktas, E. C., Senbas, Z. A., Ozturk, A. B., Ozturk, E., Ergonul, M. Tabak L, Ferhanoglu B, Cetiner M, Deniz G.
  • Rituximab desensitization in three patients with severe rituximab allergy. Curr Probl Cancer. 2017 Sep- Oct;41(5): 349-354 Öztürk E, Özyiğit LP, Öztürk AB, Akay MO, Çetiner M, Ferhanoğlu B.
  • Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma Leuk Lymphoma. 2017 May;58(5):1114-1122 Falay O, Öztürk E, Bölükbaşı Y, Gümüş T, Örnek S, Özbalak M, Çetiner M, Demirkol O, Ferhanoğlu B.
  • Implementation of an antimicrobial stewardship program for patients with febrile neutropenia Am J Infect Control. 2017 Nov 22. pii: S0196-6553(17) 31136-7. doi: 10.1016/j.ajic.2017.09.030. [Epub ahead of print] Madran B, Keske Ş, Tokça G, Dönmez E, Ferhanoğlu B, Çetiner M, Mandel NM, Ergönül Ö
  • Iron deficiency and anemia in heart failure Turk Kardiyol Dern Ars. 2017 Mar;45(Suppl 2):1-38 Çavuşoğlu Y, Altay H, Çetiner M, Güvenç TS, Temizhan A, Ural D, Yeşilbursa D, Yıldırım N, Yılmaz MB.
  • Diagnosis and treatment of iron deficiency anemia in patients with inflammatory bowel disease and gastrointestinal bleeding: iron deficiency anemia working group consensus report. Akpınar H, Çetiner M, Keshav S, Örmeci N, Törüner M.
  • Complete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report. Indian J Hematol Blood Transfus. 2016 Jun;32(Suppl 1):178-80 Bekoz HS, Kantarcioglu B, Tecimer T, Uskent N, Cetiner M, Ferhanoglu B, Sargin D.
  • Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis. Leuk Lymphoma. 2016 May;57(5):1211-4. Öztürk E, Özbalak M, Berk S, Erdoğan I, Avşar E, Dolgun A, Çetiner M, Mandel NM, Yalnız FF, Elverdi T, Salihoğlu A, Eşkazan AE, Ar MC, Öngören Ş,
  • Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease. Blood Purif. 2016 Jun 18;42(2):160-167. Solak Y, Cetiner M, Siriopol D, Tarim K, Afsar B, Covic A, Kanbay M.
  • GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro Hum Reprod. 2015 Dec;30(12):2912-25. Bildik G, Akin N, Senbabaoglu F, Sahin GN, Karahuseyinoglu S, Ince U, Taskiran C, Selek U, Yakin K, Guzel Y, Ayhan C, Alper E, Cetiner M, Balaban B,
  • Diagnostic contribution of (18) F-FDG-PET/CT in fever of unknown origin Int J Infect Dis. 2014; 19; 53-8 Tokmak H, Ergönul O, Demirkol O, Cetiner M, Ferhanoglu B
  • Nonleukemic ureteral granulocytic sarcoma presenting with unilateral urinary obstruction and Hematuria Case Rep Urol. 2013 2013;2013:861232. doi: 10.1155/2013/861232. Epub 2013 Aug 19. Acar O, Esen T, Tecimer T, Cetiner M, Peker O, Musaoğlu A
  • Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in relapse setting: two case reports and a review of literature Transfusion. 2013 53 (7): 1586-93 Yilmaz M, Eskazan AE, Unsal A, Taninmis H, Kara E, Cetiner M, Ferhanoglu B.
  • Azacitidine has limited activity in `real life'' patients with MDS and AML: a single centre experience Hematol Oncol 2011; 29: 1?6 Ozbalak M, Cetiner M, Bekoz H, Atesoglu EB, Ar C, Salihoglu A, Tuzuner N, Ferhanoglu B.
  • Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid J Bone Miner Metab. 2009;27(4):435-43 Cetiner S, Sucak GT, Kahraman SA, Akı SZ, Kocakahyaoglu B, Gultekin SE, Cetiner M, Haznedar R.
  • Bortezomib: A New Therapeutic Option for POEMS Syndrome Eur J Haematol. 2009 Sep 3. 84(2):175-7 Kaygusuz I, Tezcan H, Cetiner M, Kocakaya O, Uzay A, Bayik M.
  • L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death Cell Biol Toxicol 22 (1), 47-60, 2006 Şener, G., Eksioglu-Demiralp, E., Cetiner, M., Ercan, F., Şirvancı, S., Gedik, N., Yeğen, BC
  • Beta-Glucan amoliorates methotrexate-induced oxidative organ injury via its antioxidant and immunomodulatory effects Eur J Pharmacol. 2006 Aug 7;542(1-3):170-8 Şener G, Eksioglu-Demiralp, E, Çetiner M, Ercan F, Yeğen BC.
  • Tar.ine protects against methotrexate-induced toxicity and inhibits leucocyte death Toxicology and Applied Pharmacology 209 (1), 39-50 (2005) Cetiner, M., Şener, G., Şehirli, Ö., Eksioglu-Demiralp, E., Ercan, F., Şirvancı, S., Gedik, N., Akpolat, S., Tecimer, T., Yeğen, BC
  • Non-B, non-T Neoplasms with Lymphoblast Morphology: Further Clarification and Classification Am J Surg Pathol, 28, 835-837 (2004). Özdemirli, M., Cetiner, M
  • Hairy Cell Leukemia in Father and Son Med Oncol, 20, 375-378 (2003). Cetiner, M., Adıgüzel, C., Argon, D., Ratip, S., Ekşioğlu-Demiralp, E., Tecimer, T., Bayık, M.
  • Effect of Interferon-alpha-2a on Neutrophil Adhesion and Phagocytosis in Chronic Myeloid Leukemia and Behcet?s Disease Clin Rheumatol, 21, 211-214 (2002). Kartı, S., Ovalı, E., Ratip, S., Cetiner, M., Direskeneli, H., Bayık, M., Akoğlu, T
  • COMPARISON OF TWO CRYOPRESERVATION METHOD ACCORDING TO STEM CELL VIABILITY AND COLONY FORMING CAPACITY International Journal of Hematology and Oncology, 28(4), 171-177. KARTI, S. S., ADIGÜZEL, C., YILMAZ, M., ÇETİNER, M., RATİP, S., EKŞİOĞLU, E., ... & BAYIK, M.
  • Clinical Microbiological Case: Chronic Disseminated Candidiasis Clinical Microbiology and Infection, 8, 435-436 (2002). Ratip, S., Odabaşı, Z., Kartı, S., Cetiner, M., Yeğen, C., Çerikçioğlu, N., Bayık, M., Korten, V
  • Effectivness of FLAG chemotheraphy in refractory or relapsed acute myeloid leukemia Turk. J. Haematol, 18, 53-58.(2001) Ratip, S., Eryüksel, E., Odabaşı, Z., Çetiner, M., Özen, Y., Ovalı, E., ... & Bayık, M.
  • Normal Pressure Hydrocephalus Associated with Chronic Alpha Interferon Treatment: A Case Report Turk J Haematol, 17(1), 33-35.(2000) Ratip, S., Budak-Alpdoğan, T., Alpdoğan, Ö., Çetiner, M., Karti, S., ELMACI, İ., & Bayik, M.
  • Effects of Omeprazole on Gallbladder Contraction in Humans Hepatogastroenterology, 47, 346-348 (2000). Kapıcıoğlu, S., Baki, A., Arslan, M., Cetiner, M., Cihanyurdu, N.
  • Effects of angiotensin converting enzyme inhibitors in healthy rats and in rats with carbon tetrachloride-induced toxic hepatitis Turkish Journal of Medical Sciences, 30(4), 321-326.(2000) OVALI, E., ÇETİNER, M., RATİP, S., AYDIN, F., TEKELİOĞLU, Y., KARTI, S., ... & AĞAOĞLU, N.
  • Role of Hepatocyte Growth Factor in the Development of Dendritic Cells from CD 34+ Bone Marrow Cells Haematologica, 85, 464-469 (2000). Ovalı, E., Ratip, S., Kibaroğlu, A., Tekelioğlu, Y., Cetiner, M., Kartı, S., Aydın, F., Bayık, M., Akoğlu, T.
  • Measurement of unconjugated hyperbilirubinemia in Gilbert''s syndrome during compulsory fasting Marmara Medical Journal, 12(4), 171-174.(1999) Kapıcıoğlu, S., Çetiner, M., & Baki, A.
  • Action of Buffered Aspirin (Alka-Seltzer)''on Gastric Mucosal Injury in Humans Annals of Medical Sciences, 8, 48-51.(1999) Kapicioglu, S., Cetiner, M., & Arslan, M.
  • Bone marrow transplantation data for marmara university school of medicine: 1989-1998 Marmara Medical Journal, 11(4), 204-209.(1998) Çetiner, M., Ratip, S., Ovalı, E., Kartı, S., Bayık, M., & Akoğlu, T.
  • The effect of somatostatin analogue (SMS 201-995) on renal function in patients with decompansated cirrhosis and healthy volunteers Turk J Gastroeruerol, 7, 22-26.(1996) CETINER, M., OVALI, E., YIGITER, Y., & KAPICIOGLU, S.

INFORMATION FORM WITH REGARD TO OBTAINING AND PROCESSING OF PERSONAL DATA

Acıbadem Sağlık Hizmetleri ve Ticaret A.Ş. (“Acıbadem”) and Acıbadem’s controlling shareholders, parent companies and affiliates (hereinafter to be collectively referred to as “Acıbadem Group”) may, acting as “Data Supervisor” under the Law on Protection of Personal Data no. 6698 (the “Law”) and other pertinent laws and regulations, process your personal data within the following frame and in strict compliance with the Basic Healthcare Services Law no. 3359, the Governmental Decree-Law on Organization and Duties of the Ministry of Health and its Affiliated Companies no. 663, the Private Hospitals Regulation, and other regulations of the Ministry of Health, and other applicable laws and provisions.

1. Obtaining and Processing of Personal Data, and Purposes of Processing:

Your personal data is collected and obtained verbally, in writing, or in visual or electronic media, through call center, internet site, verbally, in writing or similar other channels for conduct of such services as protection of public health, preventive medicine, medical diagnosis, treatment and maintenance services offered by Acıbadem Group, or for planning and management of healthcare services and financing, and in accordance with the fields of business of Acıbadem Group Companies. Your general personal data and special personal data, especially your healthcare data, may be processed by the Group to a limited extent for all and any purposes, including, but not limited to, the following purposes:

All kinds of your personal data obtained by Acıbadem Group (including, but not limited to, your special personal data) may be processed for the following purposes:

Your personal data obtained and processed pursuant to the applicable laws and regulations may be transferred to physical archives and/or information systems of Acıbadem or Acıbadem Group and may be kept and stored both in digital and in physical platforms.

2. Transfer of Personal Data

Your personal data may be shared by Acıbadem and Acıbadem Group with companies included in Acıbadem Group or with private insurance companies, Ministry of Health and its sub-units, Social Security Agency, Security General Directorate and other security forces, General Directorate of Population and Census, Turkish Pharmacists’ Association, courts and all kinds of other juridical authorities, central etc. third parties, your authorized representatives and agents, and third parties offering consulting and advice services to us, including, but not limited to, lawyers, tax and financial consultants and auditors, and our business partners and other third parties acting in cooperation with us for further development or performance of healthcare services for the purposes cited above, also including regulatory and supervisory bodies and authorities, and official authorities, for the purposes of processing listed above, in accordance with the Law and other applicable laws and regulations.

3. Methods and Legal Causes of Obtaining of Personal Data

Your personal data are collected and processed in all kinds of verbal, written, visual or electronic media, for the purposes listed hereinabove, and for performance of all kinds of works included in the fields of business of Acıbadem within the legal framework, and accordingly, for full and proper performance of all kinds of contractual and legal duties and obligations of Acıbadem. Legal causes of collection and acquisition of your personal data are the pertinent provisions of:

Furthermore, as stipulated in 3rd paragraph of article 6 of the Law, personal data relating to health may also be processed by persons under secrecy obligations or by authorized official entities and organizations, without being liable to receive prior explicit consent of the relevant purpose, only for protection of public health, preventive medicine, medical diagnosis, treatment and maintenance services, and for planning and management of healthcare services and financing.

4. Your Rights Regarding Protection of Personal Data

Pursuant to the Law and other relevant applicable laws and regulations, you are entitled:

If at any time you use any one or more of your aforesaid rights, the relevant information will be transmitted to you clearly and in an understandable manner, in writing or in electronic media, by using the communication data and information provided by you.

5. Data Security

Acıbadem protects your personal data in full and strict compliance with all technical and administrative security controls required to be taken in accordance with information security standards and procedures. Said security actions and measures are taken and provided at a level appropriate for the probable risks by also taking into consideration the technological possibilities.

6. Complaints and Communications

Your personal data are protected within the frame of the available technical and administrative possibilities, and the required security actions and measures are taken and provided at a level appropriate for the probable risks by also taking into consideration the technological possibilities.

By filling in the “Application Form Pursuant to the Law on Protection of Personal Data” given at the , “https://www.acibadem.com.tr/acibademonline/hastaverilerinkorunmasi.html” web address, you may transmit and submit your legal requests:

You are hereby kindly requested to transmit your legal requests under the Law by filling in the “Application Form Pursuant to the Law on Protection of Personal Data” given at the https://www.acibadem.com.tr/acibademonline/hastaverilerinkorunmasi.html web address and sending it to us by the communication means set forth in the form.

TOP